Search Results

CNNC Headway's 13C-Urea Synthesis Control Method Patent Wins China Patent Excellence Award

On August 28, the China National Intellectual Property Administration officially released the decision on the 26th China Patent Award, and CNNC Headway's invention patent "A 13C-Urea Synthesis Control Method" won the China Patent Excellence Award. This patented technology addresses key technical bottlenecks in the batch production of carbon [13C]-urea API, establishing a set of synthesis control methods that provide technical support for the large-scale and stable production of the relevant API. The application of this technology helps enhance the self-sufficiency capability of the domestic urea [13C] breath diagnostic industry chain. CNNC Headway has long been deeply engaged in the breath diagnostic field, with sustained investment in innovative R&D, quality control, clinical adaptation, and industry chain layout...

2026-09-01

China-led International Standard for Estimating RBE-Weighted Absorbed Dose from Acute Exposure Approved for Initiation

According to the International Organization for Standardization (ISO), the international standard ISO25600 "Estimation Method for RBE (Relative Biological Effectiveness)-Weighted Absorbed Dose from Acute Exposure," led by the China Institute of Atomic Energy, has been officially approved for initiation. This is a general methodology international standard led by China in the global field of nuclear and radiation emergency dose assessment. It can provide important support for the rapid estimation and evaluation of acute doses, decision-making on emergency protective actions, international notification and communication, as well as emergency training, exercises, and scientific research, helping to strengthen the scientific rigor and timeliness of global nuclear emergency response, and enhance response capability and standardization. Nuclear and radiation emergency response is a vital guarantee for the sustained and healthy development of the nuclear energy industry...

2026-08-31

CGN and CSSC Deepen Cooperation in Nuclear Power and New Energy Sectors

On August 28, Pang Songtao, Deputy Secretary of the Party Committee and General Manager of China General Nuclear Power Group Co., Ltd. (CGN), met with Xu Peng and his delegation, Secretary of the Party Leadership Group and Chairman of China State Shipbuilding Corporation Limited (CSSC), at the CGN Tower. The two sides conducted in-depth exchanges on cooperation in areas such as nuclear power, new energy, industrial software, and technological innovation. Peng Yuanpu, Member of the Party Leadership Group and Deputy General Manager of CSSC, Ma Yunxiang, Assistant to the General Manager, Cai Zhen, Member of the Standing Committee of the Party Committee and Deputy General Manager of CGN, and Zhou Jianping, Member of the Party Committee of CGN, Vice President and General Counsel of CGN Power, attended the meeting. Pang Songtao extended a warm welcome to Xu Peng and his delegation. He noted that the cooperation between CGN and CSSC began with the Daya Bay Nuclear Power Plant and has spanned over four decades, with cooperation areas gradually expanding from nuclear power to environmental governance, new energy development, industrial software, and other fields, achieving fruitful results in areas such as nuclear emergency diesel generators and wind power equipment. Looking toward the “15th Five-Year Plan” period, he expressed the hope that both sides would further expand cooperation in new areas such as equipment manufacturing and technological innovation while consolidating the existing cooperation foundation, so as to better serve the national strategic agenda.

2026-08-31

Two Projects of the National Natural Science Foundation of China Approved for the National Institute for Radiological Protection, China CDC

On August 26, the National Natural Science Foundation of China (NSFC) announced the review results of the centralized application projects for the fiscal year 2026. The National Institute for Radiological Protection, China CDC, was approved for two NSFC projects, with research directions covering radon exposure monitoring, radiological health, and screening of lung cancer-related biomarkers. Among the approved projects, the proposal titled "New Strategy for Radon Exposure Monitoring: Visualization and Mechanism Study of Adsorption-Detection Integrated Gold Nanoparticle Materials" submitted by Associate Researcher Song Yanchao received support from the Department of Mathematical and Physical Sciences; the proposal titled "Preliminary Study and Validation of Screening Lung Cancer-Related Biomarkers in Radon-Exposed Miners Based on Methylation Chips and RNA-seq" submitted by Assistant Researcher Zhang Pinhua received support from the Department of Health Sciences.

2026-08-31

Domestically Produced Nuclear-Grade Resins Fully Verified and Ready for Use

On August 28, China General Nuclear Power Group (hereinafter referred to as CGN) announced that five nuclear-grade resin products developed under its leadership have all been put into engineering application, with a cumulative total of 12 batches used at nuclear power plants including Daya Bay, Ningde, Yangjiang, Taishan, and Hongyanhe. Among them, the first product has been operating stably for over three years in the steam generator blowdown system (APG system) of nuclear power plants, with key performance indicators comprehensively outperforming imported counterparts of the same category, and the domestic nuclear-grade resin production line. Nuclear-grade resins are known as the "kidneys" of nuclear power water treatment systems, serving as core materials that ensure stable water chemistry indicators of nuclear power units and prevent equipment corrosion. For a long time, these materials have been highly dependent on imports, posing supply security risks such as long delivery cycles, unstable batch quality, and rising prices year by year.

2026-08-29

China's First Enterprise-Level Synchrotron Radiation Technology Application Research Platform Inaugurated in Shanghai

The Sinopec Shanghai Synchrotron Radiation Facility Energy and Chemical Science Laboratory, invested by Sinopec and jointly built with the Shanghai Advanced Research Institute of the Chinese Academy of Sciences, and based on the Shanghai Synchrotron Radiation Facility (SSRF) major scientific infrastructure, was recently inaugurated in Shanghai Zhangjiang Science City. This laboratory is the first enterprise-level synchrotron radiation technology application research platform in China. According to reports, the laboratory consists of three beamline stations and auxiliary laboratories, and will provide technical support and services for basic scientific research conducted by Sinopec and public users, with a focus on oil and gas exploration and development, petroleum refining and chemical engineering, and new energy and new materials. Once the platform is completed, it will help enhance the enterprise's capabilities in forward-looking and fundamental research, and provide scientific research support for cultivating new quality productive forces in China's energy and chemical industry.

2026-08-29

China Isotope & Radiation Plans to Invest RMB 400 Million in Zhejiang Nuclear Technology Application Industry Fund

China Isotope & Radiation Corporation announced on August 28 that its board of directors has approved entering into a partnership agreement with CNNC, CNNC Capital, CNNC Fund, National Industry Investment Fund, Zhejiang Venture Capital Guidance Fund, Jiaxing Changchuang Industrial Investment, and Haiyan County State-owned Capital Investment to jointly establish CNNC (Zhejiang) Nuclear Technology Application Industry Investment Fund Partnership (Limited Partnership). According to the announcement, the fund will be registered in Jiaxing City, Zhejiang Province, with partners intending to subscribe to a total capital contribution of RMB 3 billion. Among them, China Isotope & Radiation plans to contribute RMB 400 million from internal resources, accounting for 13.33% of the fund's total subscribed capital; CNNC Fund, as the general partner, plans to contribute RMB 30 million, accounting for 1%; the National...

2026-08-29

CNNC Changchun Nuclear Medicine Base Obtains Production License

On August 28, the Jilin Provincial Drug Administration approved and issued the "Radiopharmaceutical Production License" to Changchun Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as "Changchun Hi-Tech"), a subsidiary of Atomic Hi-Tech under China Isotope & Radiation Corporation (CIRC). The acquisition of this license marks that Changchun Hi-Tech is now fully qualified for the production of technetium-labeled drugs. Radiopharmaceuticals are characterized by short half-lives, high transportation requirements, and strict time sensitivity. Long-distance transportation not only increases transportation and time costs but also poses greater challenges to the stability and timeliness of clinical medication. With the production qualification, Changchun Hi-Tech will be able to complete the production and distribution of technetium-labeled drugs locally in Jilin Province, which will help improve the clinical use of nuclear medicine in the Northeast region...

2026-08-29

CIAE Neutron Measurement Patent for Nuclear Waste Wins China Patent Excellence Award

On August 28, the results of the 26th China Patent Award, the highest government honor in China's intellectual property field, were announced. The invention patent for the calibration method of a neutron measurement device for drummed nuclear waste, completed by Zhu Liqun, Senior Engineer, and Xu Xiaoming, Associate Researcher, from the Department of Radiochemistry at the China Institute of Atomic Energy (CIAE), won the China Patent Excellence Award. Since 2020, CIAE has won the China Patent Award for six consecutive sessions, securing a total of 11 awards including 2 gold and 1 silver medals, further demonstrating the institute's formidable strength in technological innovation and intellectual property. The calibration method invention patent for the neutron measurement device for drummed nuclear waste has achieved multiple world firsts...

2026-08-29

China Unicom Yantai Branch and CNNC Shandong Build 5G Dedicated Network for Nuclear Power

Recently, the 5G dedicated network project jointly built by China Unicom Shandong Yantai Branch and CNNC Shandong was officially deployed and put into operation. Targeting the requirements of nuclear power scenarios for communication network security, reliability, and low latency, the project introduces technologies such as 5G dedicated networks, edge computing, artificial intelligence, and big data to promote the implementation of digital capabilities in nuclear power park construction and production support scenarios. CNNC Shandong, affiliated with China National Nuclear Corporation, undertakes tasks related to nuclear power unit power generation and grid connection. During project construction, China Unicom Shandong Yantai Branch, in collaboration with Huawei, adopted end-to-end domestically produced equipment, achieving independent controllability in both hardware and software, filling the gap in domestic 5G dedicated network construction in the nuclear power sector...

2026-08-28

Leadership Adjustment of Chairman and Party Secretary of China Huaneng Group Co., Ltd.

On August 28, 2026, China Huaneng Group Co., Ltd. held a meeting for management personnel at the middle level and above. A relevant official from the Organization Department of the CPC Central Committee announced the Party Central Committee's decision on the adjustment of the Chairman and Party Secretary of China Huaneng Group Co., Ltd.: Comrade Bai Yong was appointed as Chairman and Party Secretary of China Huaneng Group Co., Ltd., and was relieved of his duties as Director, President, and Deputy Party Secretary of COFCO Corporation; Comrade Wen Shugang was relieved of his duties as Chairman and Party Secretary of China Huaneng Group Co., Ltd. The relevant appointments and removals shall be handled in accordance with applicable laws and the company's articles of association...

2026-08-28

CNNC Fuyuan (Beijing) Technology Co., Ltd. officially established, focusing on accelerator and radiation technology equipment

On August 26, 2026, CNNC Fuyuan (Beijing) Technology Co., Ltd. (abbreviated as: CNNC Fuyuan) was officially established. CNNC Fuyuan is a joint venture between China Isotope & Radiation Corporation (CIRC) and CNNC Atomic Energy Institute Technology Co., Ltd., with nuclear technology equipment as its core business and radiation technology empowering industrial upgrading. Leveraging the Atomic Energy Institute's profound accumulation in accelerator technology over more than 70 years, as well as CIRC's market-oriented industrialization capabilities, the company builds a deeply integrated industry closed loop encompassing research, education, application, and utilization, strengthening and complementing the nuclear technology equipment industry chain. Looking ahead, CNNC Fuyuan will adhere to the dual-drive approach of independent innovation and achievement transformation, starting with accelerators, breaking through the boundaries of single products, and extending toward full-spectrum radiation technology,...

2026-08-28

Huzhou, Zhejiang Launches Phase I "Drug-Device Combination" Clinical Trial for the Province's First BNCT System

Recently, the Boron Neutron Tumor Treatment Center at Huzhou Hospital Affiliated to Zhejiang University School of Medicine has drawn attention with the introduction of the province's first Boron Neutron Capture Therapy (BNCT) system. Previously, the system had already initiated a Phase I BNCT drug-device combination clinical trial. According to the system developer, Huapeng Neutron Technology (Hangzhou) Co., Ltd., BNCT is a radiotherapy technique combining drugs and devices, with its core lying in the coordinated use of boron-containing drugs and neutron irradiation. After entering the human body, the boron-containing drug can be absorbed by tumor cells; subsequent neutron beam irradiation triggers a localized reaction to achieve targeted radiotherapy against tumor cells. Unlike conventional radiotherapy, which typically employs fractionated irradiation over a longer treatment course, BNCT emphasizes selective targeting of tumor cells, aiming to reduce damage to surrounding healthy tissues and lower radiotherapy-related side effects such as hair loss and immunosuppression.

2026-08-27

Department of Nuclear Medicine at the Affiliated Hospital of Southwest Medical University Completes Its First PET/CT-Guided Interventional Puncture Procedure

From August 21 to 22, Professor Sun Long from the PET Center of the First Affiliated Hospital of Xiamen University was invited to the Department of Nuclear Medicine at the Affiliated Hospital of Southwest Medical University for academic exchange, and on the following day provided on-site guidance for the hospital's first PET/CT-guided interventional puncture procedure. The successful completion of this procedure marks a new clinical practice milestone for the department in the field of interventional nuclear medicine. On August 21, Professor Sun Long delivered a special lecture titled "Exploration of Clinical Integrated Application of Diagnostic Nuclear Medicine and Interventional Nuclear Medicine Based on the PET Platform," focusing on how the PET platform extends from disease diagnosis and precise localization to interventional diagnosis and treatment. Drawing on clinical practice and typical cases, he introduced the application of interventional nuclear medicine in lesion...

2026-08-27

Lanzhou Taiji Completes Key Commissioning of First Domestic Multi-Ion Therapy Device HiTS400

The first domestically produced multi-ion therapy device HiTS400, independently developed by Lanzhou Taiji and installed at Shandong Cancer Hospital, recently completed phased joint commissioning. After one week of operational testing, all beam parameters of the device met or exceeded contractual requirements, laying the foundation for subsequent clinical registration work. According to reports, HiTS400 is a medical ion accelerator independently developed by Lanzhou Taiji with full intellectual property rights. It can stably deliver four ion species: C^6+, H^+, He^2+, and O^8+, and is equipped with multi-angle fixed treatment nozzles and a lightweight superconducting heavy-ion rotating gantry, integrating modulated scanning technology to advance the development and application of multi-ion combined therapy devices. On August 14, 2026, the device obtained an amendment to its Radiation Safety License from the Ministry of Ecology and Environment, granting qualification for commissioning and operation. In the early morning of August 20, the equipment achieved stable acceleration and precise extraction of carbon ion beams. Measured data show that the particle number after synchrotron acceleration reached 3.26E9 ppp, the terminal particle number reached 3.02E9 ppp, the extraction efficiency was 92%, and beam stability was no less than 95%.

2026-08-26